News

Optimer is eligible to receive a one-time, up-front cash payment of $20m and additional cash payments of up to $70m upon the achievement of certain regulatory and commercial

The grant is from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. PLx Pharma and UTHealth are working to reduce the GI toxicity of

The trial was designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide. The study met its primary end-point,

The collaboration aims to expand the footprint of Intelsius and its core strategy of offering products globally with local supply. Intelsius CEO David Walsh said the company’s partnership

Omontys injection is a synthetic, pegylated, peptide-based erythropoiesis stimulating agent (ESA). Nektar provides its partner Affymax with its proprietary PEGylation technology for use in Omontys. Two Phase 3

The goal of Compugen Inc., a wholly owned subsidiary of Compugen Ltd., is to translate the growing portfolio of novel mAb targets being discovered and validated by the

The study, which is being conducted at multiple sites across Southern Ontario, will evaluate the safety and pharmacokinetics of single ascending doses of TTI-1612 in IC/BPS patients. TTI-1612

The study reported that significantly more patients achieved at least a 75% improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo

The launch of bioequivalent generic version of SEROQUEL tablets is followed by the FDA approval of Dr Reddy’s ANDA. Quetiapine fumarate tablets in 25mg and 50mg are available